Xenon Pharmaceuticals to Present at the William Blair Biotech Focus Conference 2022
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Xenon Pharmaceuticals (Nasdaq:XENE) will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, in New York, NY. The company is focused on developing innovative therapeutics for neurological disorders, particularly in the area of epilepsy. A webcast of their fireside chat presentation will be available on their Investors section of the website. Xenon aims to address significant unmet medical needs through its clinical-stage product pipeline.
Details
News Market Reaction – XENE
The recorded move for XENE in the trading session of this news was -1.30%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BURNABY, British Columbia, July 11, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that management will participate in a fireside chat presentation and one-on-one investor meetings at the William Blair Biotech Focus Conference 2022 to be held July 12-13, 2022 in New York, NY.
A webcast of the fireside chat company presentation is available on the “Investors” section of Xenon's website at investor.xenon-pharma.com.
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.